Clinical Research Advantage (CRA), the US provider of clinical-trial management and other research services to pharmaceutical companies and contract research organisations, has announced a strategic alliance with Quintiles to drive patient enrolment into community-based studies.
Billing itself as the largest community-based network of clinical trial sites in the US, CRA said the alliance would facilitate participation in Phase II-IV trials across a wide range of disease areas, with an emphasis on safety, study efficiencies and “excellent” quality data.
According to the Tempe, Arizona-based company, it is the first therapeutically aligned network of family medicine community-based sites to be chosen by Quintiles for a strategic partnership.
As Lindy Jones, senior vice president, Integrated Site Services for Quintiles, pointed out, many chronic conditions such as diabetes and heart disease are now managed in the community.
“It is imperative that these patient populations have the opportunity to participate in studies and be a part of the quest to develop new and better medicines for conditions that have a significant impact on both individuals and society,” Jones commented.